Ana holds a PhD in Biomedical Sciences from the Faculty of Medicine, University of Lisbon, Portugal. Her main contributions as a researcher were in molecular biology, parasitology and translational research. Currently, she is highly interested and working in innovation in healthcare and science communication.
Twice‐weekly Ninlaro (ixazomib) plus Revlimid (lenalidomide) and dexamethasone can improve long-term outcomes in patients with newly diagnosed multiple myeloma, although it’s likely more toxic than once-weekly Ninlaro, according to ... Read more
Adding Pomalyst (pomalidomide) to a combination of Velcade (bortezomib) and dexamethasone significantly extended the time until disease worsening or death in patients with relapsed or refractory multiple myeloma, updated Phase 3 ... Read more
The University of Alabama at Birmingham (UAB) is recruiting patients with newly diagnosed multiple myeloma for a Phase 2 trial evaluating an innovative treatment approach with the goal of ... Read more
Selinexor, the lead oral therapy developed by Karyopharm Therapeutics, received Fast Track designation by the U.S. Food and Drug Administration (FDA), for the treatment of refractory multiple myeloma patients — those ... Read more
SELLAS Life Sciences’ Galinpepimut-S vaccine more than doubles the time it takes for high-risk multiple myeloma patients’ cancer to worsen, a Phase 2 clinical trial shows. Myeloma expert Guenther Koehne presented the results at the Annual ... Read more
Immune factors that drive donor T-cells to cause graft-versus-host disease (GVHD) have been found by researchers whose discovery may offer new opportunities for therapeutic targets to minimize the risks of ... Read more